SCHEMBL278768

SCHEMBL278768

CC(C)(C)CNc1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.55
GPR39 O43194 2/20 0.54
FABP1 P07148 1/20 0.53
FABP6 P51161 1/20 0.53
CYP2C19 P33261 1/20 0.53
NUDT1 P36639 1/20 0.51
CYP1A2 P05177 1/20 0.50
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 2/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
CYP2D6 P10635 1/20 0.46
MEN1 O00255 1/20 0.45
MAPK10 P53779 1/20 0.45
GFER P55789 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29846927 1.00 CXCR4 (0.55) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL6702893 0.85 CXCR4 (0.52) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL7383486 0.85 CXCR4 (0.52) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL17700372 0.85 CXCR4 (0.52) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL17700674 0.85 CXCR4 (0.52) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL17700596 0.85 CXCR4 (0.56) CXCR4FABP1FABP6CYP2C19CYP1A2
Hydrochloric Acid SCHEMBL17700125 0.83 CXCR4 (0.50) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL17700790 0.82 CXCR4 (0.49) CXCR4GPR39FABP1FABP6CYP2C19
SCHEMBL4718056 0.82 CXCR4 (0.49) CXCR4FABP1FABP6CYP2C19NUDT1
SCHEMBL31610584 0.81 CYP2C19 (0.59) CXCR4FABP1FABP6CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 US disclosed
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 US disclosed
US-10947237-B2 Antimicrobial compounds and methods of making and using the same BioVersys AG (CH) 2021-03-16 US disclosed
US-10829458-B2 Substituted quinazoline compounds and methods of use thereof ARAXES PHARMA LLC (US) 2020-11-10 US disclosed
US-20190284144-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2019-09-19 US disclosed
EP-3031799-B1 AROMATIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-04-04 EP disclosed
US-20180065966-A1 Antimicrobial Compounds And Methods Of Making And Using The Same MELINTA THERAPEUTICS, INC. 2018-03-08 US disclosed
US-20180065966-A1 Antimicrobial Compounds And Methods Of Making And Using The Same MELINTA THERAPEUTICS, INC. 2018-03-08 US disclosed
US-9776962-B2 Aromatic compounds with GPR40 agonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
US-20160297774-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2016-10-13 US disclosed
US-8324221-B2 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-8324221-B2 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-03 US disclosed
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-03 US disclosed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 US disclosed
EP-0977743-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-02-09 EP disclosed
WO-1998049152-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284144-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS CXCR4 415/4885GPR39 3149/4885FABP1 4408/4885
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS HDAC1, CDK9, CDK2 CXCR4 3120/4885GPR39 3422/4885FABP1 2942/4885
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, PGM2 CXCR4 3759/4885GPR39 2663/4885FABP1 386/4885
US-20160297774-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS CXCR4 415/4885GPR39 3149/4885FABP1 4408/4885
US-20110053959-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, PIK3CA CXCR4 1433/4885GPR39 2839/4885FABP1 2395/4885
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN CXCR4 397/4885GPR39 1143/4885FABP1 827/4885
US-10829458-B2 Substituted quinazoline compounds and methods of use thereof KRAS, NRAS, HRAS CXCR4 415/4885GPR39 3149/4885FABP1 4408/4885
US-20180065966-A1 Antimicrobial Compounds And Methods Of Making And Using The Same LPO, MPO, CAT CXCR4 3103/4885GPR39 4851/4885FABP1 1341/4885
US-10947237-B2 Antimicrobial compounds and methods of making and using the same LPO, MPO, CAT CXCR4 3103/4885GPR39 4851/4885FABP1 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.